Biomarkers for monitoring chemotherapy-induced cardiotoxicity

References

• Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53:2231–47
   PubMed Web of Science ®Google Scholar
• Yeh ET. Cardiotoxicity induced by chemotherapy and antibody therapy. Annu Rev Med 2006;57:485–98
   PubMed Web of Science ®Google Scholar
• Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 2007;25:4952–60
   PubMed Web of Science ®Google Scholar
• Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2008;100:1368–79
   PubMed Web of Science ®Google Scholar
• Lenneman CG, Sawyer DB. Cardio-oncology: an update on cardiotoxicity of cancer-related treatment. Circ Res 2016;118:1008–20
   PubMed Web of Science ®Google Scholar
• Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol 2014;64:938–45
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Franco VI, Miller TL, et al. Cardiovascular disease in adult survivors of childhood cancer. Annu Rev Med 2015;66:161–76
   PubMed Web of Science ®Google Scholar
• Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900–5
   PubMed Web of Science ®Google Scholar
• Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med 2002;137:631–9
   PubMed Web of Science ®Google Scholar
• Monsuez JJ, Charniot JC, Vignat N, Artigou JY. Cardiac side-effects of cancer chemotherapy. Int J Cardiol 2010;144:3–15
   PubMed Web of Science ®Google Scholar
• Horacek JM, Pudil R, Jebavy L, et al. Assessment of anthracycline-induced cardiotoxicity with biochemical markers. Exp Oncol 2007;29:309–13
   PubMedGoogle Scholar
• Lipshultz SE, Grenier MA, Colan SD. Doxorubicin-induced cardiomyopathy. N Engl J Med 1999;340:653–4; author reply 655
   PubMed Web of Science ®Google Scholar
• Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 1978;62:873–9
   PubMedGoogle Scholar
• Kremer LC, Caron HN. Anthracycline cardiotoxicity in children. N Engl J Med 2004;351:120–1
   PubMed Web of Science ®Google Scholar
• Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302–14
   PubMed Web of Science ®Google Scholar
• Rinehart JJ, Lewis RP, Balcerzak SP. Adriamycin cardiotoxicity in man. Ann Intern Med 1974;81:475–8
   PubMed Web of Science ®Google Scholar
• Sorensen K, Levitt GA, Bull C, et al. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer 2003;97:1991–8
   PubMed Web of Science ®Google Scholar
• Ray JC, Cho P, Dragon M, Graham CG. A case of 5-fluorouracil-induced cardiac arrest. J Emerg Med 2016;50:e1–6
   PubMed Web of Science ®Google Scholar
• Vargo CA, Blazer M, Reardon J, et al. Successful completion of adjuvant chemotherapy in a patient with colon cancer experiencing 5-fluorouracil-induced cardiac vasospasm. Clin Colorectal Cancer 2016;15:e61–3
   PubMed Web of Science ®Google Scholar
• Rateesh S, Shekar K, Naidoo R, et al. Use of extracorporeal membrane oxygenation for mechanical circulatory support in a patient with 5-fluorouracil induced acute heart failure. Circ Heart Fail 2015;8:381–3
   PubMed Web of Science ®Google Scholar
• Marechal S, Racaru V, Houbiers G, Graas MP. Pericarditis following 5-fluorouracil administration. Rev Med Liege 2015;70:360–6
   PubMedGoogle Scholar
• Iskandar MZ, Quasem W, El-Omar M. 5-Fluorouracil cardiotoxicity: reversible left ventricular systolic dysfunction with early detection. BMJ Case Rep 2015;2015. pii: bcr2015209347. doi: 10.1136/bcr-2015-209347
   Google Scholar
• Sorrentino MF, Kim J, Foderaro AE, Truesdell AG. 5-Fluorouracil induced cardiotoxicity: review of the literature. Cardiol J 2012;19:453–8
   PubMed Web of Science ®Google Scholar
• Dalzell JR, Samuel LM. The spectrum of 5-fluorouracil cardiotoxicity. Anticancer Drugs 2009;20:79–80
   PubMed Web of Science ®Google Scholar
• Lamberti M, Porto S, Marra M, et al. 5-Fluorouracil induces apoptosis in rat cardiocytes through intracellular oxidative stress. J Exp Clin Cancer Res 2012;31:60
   PubMed Web of Science ®Google Scholar
• Eskandari MR, Moghaddam F, Shahraki J, Pourahmad J. A comparison of cardiomyocyte cytotoxic mechanisms for 5-fluorouracil and its pro-drug capecitabine. Xenobiotica 2015;45:79–87
   PubMed Web of Science ®Google Scholar
• Appel JM, Zerahn B, Moller S, et al. Long-term heart function after adjuvant epirubicin chemotherapy for breast cancer. Acta Oncol 2012;51:1054–61
   PubMed Web of Science ®Google Scholar
• De SR, Bertuzzi A, Basso U, et al. Non-pegylated liposomal doxorubicin plus ifosfamide in metastatic soft tissue sarcoma: results from a phase-II trial. Anticancer Res 2015;35:543–7
   PubMed Web of Science ®Google Scholar
• Dede DS, Aksoy S, Cengiz M, et al. Ifosfamide and doxorubicin combination chemotherapy for recurrent nasopharyngeal carcinoma patients. Asian Pac J Cancer Prev 2012;13:2225–8
   PubMedGoogle Scholar
• Quezado ZM, Wilson WH, Cunnion RE, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 1993;118:31–6
   PubMed Web of Science ®Google Scholar
• de Azambuja E, Ameye L, Diaz M, et al. Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy. Eur J Cancer 2015;51:2517–24
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542–50
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55:213–20
   PubMed Web of Science ®Google Scholar
• Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008;14:14–24
   PubMed Web of Science ®Google Scholar
• Nielsen D, Jensen JB, Dombernowsky P, et al. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. J Clin Oncol 1990;8:1806–10
   PubMed Web of Science ®Google Scholar
• Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002;13:699–709
   PubMed Web of Science ®Google Scholar
• Marchandise B, Schroeder E, Bosly A, et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 1989;118:92–8
   PubMed Web of Science ®Google Scholar
• Kang Y, Xu X, Cheng L, et al. Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy. Eur J Heart Fail 2014;16:300–8
   PubMed Web of Science ®Google Scholar
• Ewer MS, Ali MK, Gibbs HR, et al. Cardiac diastolic function in pediatric patients receiving doxorubicin. Acta Oncol 1994;33:645–9
   PubMed Web of Science ®Google Scholar
• Weesner KM, Bledsoe M, Chauvenet A, Wofford M. Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer 1991;68:435–8
   PubMed Web of Science ®Google Scholar
• Klewer SE, Goldberg SJ, Donnerstein RL, et al. Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. J Am Coll Cardiol 1992;19:394–401
   PubMed Web of Science ®Google Scholar
• Singh D, Thakur A, Tang WH. Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy. Curr Heart Fail Rep 2015;12:255–62
   PubMedGoogle Scholar
• Bauch M, Ester A, Kimura B, et al. Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects. Cancer 1992;69:1492–7
   PubMed Web of Science ®Google Scholar
• Feola M, Garrone O, Occelli M, et al. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol 2011;148:194–8
   PubMed Web of Science ®Google Scholar
• Ritchie JL, Singer JW, Thorning D, et al. Anthracycline cardiotoxicity: clinical and pathologic outcomes assessed by radionuclide ejection fraction. Cancer 1980;46:1109–16
   PubMed Web of Science ®Google Scholar
• Gottdiener JS, Mathisen DJ, Borer JS, et al. Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography. Ann Intern Med 1981;94:430–5
   PubMed Web of Science ®Google Scholar
• Choi BW, Berger HJ, Schwartz PE, et al. Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance. Am Heart J 1983;106:638–43
   PubMed Web of Science ®Google Scholar
• Piver MS, Marchetti DL, Parthasarathy KL, et al. Doxorubicin hydrochloride (Adriamycin) cardiotoxicity evaluated by sequential radionuclide angiocardiography. Cancer 1985;56:76–80
   PubMed Web of Science ®Google Scholar
• Alexander J, Dainiak N, Berger HJ, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 1979;300:278–83
   PubMed Web of Science ®Google Scholar
• Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 1987;82:1109–18
   PubMed Web of Science ®Google Scholar
• Palmeri ST, Bonow RO, Myers CE, et al. Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. Am J Cardiol 1986;58:607–13
   PubMed Web of Science ®Google Scholar
• Mitani I, Jain D, Joska TM, et al. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol 2003;10:132–9
   PubMed Web of Science ®Google Scholar
• Lu P. Monitoring cardiac function in patients receiving doxorubicin. Semin Nucl Med 2005;35:197–201
   PubMed Web of Science ®Google Scholar
• Corbett JR, Akinboboye OO, Bacharach SL, et al. Equilibrium radionuclide angiocardiography. J Nucl Cardiol 2006;13:e56–79
   PubMed Web of Science ®Google Scholar
• Mitra D, Basu S. Equilibrium radionuclide angiocardiography: its usefulness in current practice and potential future applications. World J Radiol 2012;4:421–30
   PubMedGoogle Scholar
• Nguyen KL, Hu P, Ennis DB, et al. Cardiac MRI: a translational imaging tool for characterizing anthracycline-induced myocardial remodeling. Curr Oncol Rep 2016;18:48
   PubMed Web of Science ®Google Scholar
• Toro-Salazar OH, Ferranti J, Lorenzoni R, et al. Feasibility of echocardiographic techniques to detect subclinical cancer therapeutics-related cardiac dysfunction among high-dose patients when compared with cardiac magnetic resonance imaging. J Am Soc Echocardiogr 2016;29:119–31
   PubMed Web of Science ®Google Scholar
• Ylanen K, Poutanen T, Savikurki-Heikkila P, et al. Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among long-term survivors of childhood cancer. J Am Coll Cardiol 2013;61:1539–47
   PubMed Web of Science ®Google Scholar
• Drafts BC, Twomley KM, D'Agostino R, Jr et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging 2013;6:877–85
   PubMed Web of Science ®Google Scholar
• Armstrong GT, Plana JC, Zhang N, et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 2012;30:2876–84
   PubMed Web of Science ®Google Scholar
• Lunning MA, Kutty S, Rome ET, et al. Cardiac magnetic resonance imaging for the assessment of the myocardium after doxorubicin-based chemotherapy. Am J Clin Oncol 2015;38:377–81
   PubMed Web of Science ®Google Scholar
• Grothues F, Moon JC, Bellenger NG, et al. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J 2004;147:218–23
   PubMed Web of Science ®Google Scholar
• Horino N, Kobayashi Y, Usui T. Elevation of lipid peroxide in children treated with a combination of chemotherapeutic agents including doxorubicin. Acta Paediatr Scand 1983;72:549–51
   PubMed Web of Science ®Google Scholar
• Espiner EA, Richards AM. Atrial natriuretic peptide. An important factor in sodium and blood pressure regulation. Lancet 1989;1:707–10
   PubMed Web of Science ®Google Scholar
• Wei CM, Heublein DM, Perrella MA, et al. Natriuretic peptide system in human heart failure. Circulation 1993;88:1004–9
   PubMed Web of Science ®Google Scholar
• Chen S, Sen S, Young D, et al. Protease corin expression and activity in failing hearts. Am J Physiol Heart Circ Physiol 2010;299:H1687–92
   PubMed Web of Science ®Google Scholar
• Yan W, Sheng N, Seto M, et al. Corin, a mosaic transmembrane serine protease encoded by a novel cDNA from human heart. J Biol Chem 1999;274:14926–35
   PubMed Web of Science ®Google Scholar
• Armaly Z, Assady S, Abassi Z. Corin: a new player in the regulation of salt-water balance and blood pressure. Curr Opin Nephrol Hypertens 2013;22:713–22
   PubMed Web of Science ®Google Scholar
• Song W, Wang H, Wu Q. Atrial natriuretic peptide in cardiovascular biology and disease (NPPA). Gene 2015;569:1–6
   PubMed Web of Science ®Google Scholar
• Pandey KN. Guanylyl cyclase/natriuretic peptide receptor-A signaling antagonizes phosphoinositide hydrolysis, Ca(2+) release, and activation of protein kinase C. Front Mol Neurosci 2014;7:75. doi: 10.3389/fnmol.2014.00075. eCollection 2014
   PubMed Web of Science ®Google Scholar
• Lisy M, Babal P. Brain natriuretic peptide—the biological marker in the diagnosis of overt congestive heart failure and myocardial ischemia. Bratisl Lek Listy 2007;108:170–3
   PubMed Web of Science ®Google Scholar
• Peng J, Jiang J, Wang W, et al. Glycosylation and processing of pro-B-type natriuretic peptide in cardiomyocytes. Biochem Biophys Res Commun 2011;411:593–8
   PubMed Web of Science ®Google Scholar
• Semenov AG, Tamm NN, Seferian KR, et al. Processing of pro-B-type natriuretic peptide: furin and corin as candidate convertases. Clin Chem 2010;56:1166–76
   PubMed Web of Science ®Google Scholar
• Kato M, Kinugawa T, Ogino K, et al. Augmented response in plasma brain natriuretic peptide to dynamic exercise in patients with left ventricular dysfunction and congestive heart failure. J Intern Med 2000;248:309–15
   PubMed Web of Science ®Google Scholar
• McNairy M, Gardetto N, Clopton P, et al. Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide. Am Heart J 2002;143:406–11
   PubMed Web of Science ®Google Scholar
• Sparano JA, Brown DL, Wolff AC. Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers. Drug Saf 2002;25:301–11
   PubMed Web of Science ®Google Scholar
• Wong SS. Strategic utilization of cardiac markers for the diagnosis of acute myocardial infarction. Ann Clin Lab Sci 1996;26:301–12
   PubMed Web of Science ®Google Scholar
• Agress CM. Ischemic heart disease: use of serum enzyme determinations in diagnosis. Calif Med 1965;103:21–6
   PubMedGoogle Scholar
• Cohen L, Djordjevich J, Jacobsen S. The contribution of isozymes of serum lactic dehydrogenase (LDH) to the diagnosis of specific organ injury with special reference to myocardial injury. Med Clin N Am 1966;50:193–209
   PubMed Web of Science ®Google Scholar
• Parmacek MS, Solaro RJ. Biology of the troponin complex in cardiac myocytes. Prog Cardiovasc Dis 2004;47:159–76
   PubMed Web of Science ®Google Scholar
• Al-Otaiby MA, Al-Amri HS, Al-Moghairi AM. The clinical significance of cardiac troponins in medical practice. J Saudi Heart Assoc 2011;23:3–11
   PubMedGoogle Scholar
• Konstantinides S, Geibel A, Olschewski M, et al. Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation 2002;106:1263–8
   PubMed Web of Science ®Google Scholar
• Panteghini M. Role and importance of biochemical markers in clinical cardiology. Eur Heart J 2004;25:1187–96
   PubMed Web of Science ®Google Scholar
• Babuin L, Jaffe AS. Troponin: the biomarker of choice for the detection of cardiac injury. CMAJ 2005;173:1191–202
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the Special Contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;18:891–975
   Web of Science ®Google Scholar
• Apple FS, Collinson PO. Biomarkers ITFoCAoC. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012;58:54–61
   PubMed Web of Science ®Google Scholar
• Sherwood MW, Kristin Newby L. High-sensitivity troponin assays: evidence, indications, and reasonable use. J Am Heart Assoc 2014;3:e000403
   PubMed Web of Science ®Google Scholar
• Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 1999;100:96–102
   PubMed Web of Science ®Google Scholar
• Arruda-Olson AM, Enriquez-Sarano M, Bursi F, et al. Left ventricular function and C-reactive protein levels in acute myocardial infarction. Am J Cardiol 2010;105:917–21
   PubMed Web of Science ®Google Scholar
• Windram JD, Loh PH, Rigby AS, et al. Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. Am Heart J 2007;153:1048–55
   PubMed Web of Science ®Google Scholar
• Brunel-Guitton C, Levtova A, Sasarman F. Mitochondrial diseases and cardiomyopathies. Can J Cardiol 2015;31:1360–76
   PubMed Web of Science ®Google Scholar
• Lenihan DJ, Stevens PL, Massey M, et al. The utility of point-of-care biomarkers to detect cardiotoxicity during anthracycline chemotherapy: a feasibility study. J Card Fail 2016;22:433–8
   PubMed Web of Science ®Google Scholar
• Suzuki T, Hayashi D, Yamazaki T, et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998;136:362–3
   PubMed Web of Science ®Google Scholar
• Sandri MT, Salvatici M, Cardinale D, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 2005;51:1405–10
   PubMed Web of Science ®Google Scholar
• Zver S, Zadnik V, Bunc M, et al. Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Int J Hematol 2007;85:408–14
   PubMed Web of Science ®Google Scholar
• Zver S, Zadnik V, Cernelc P, Kozelj M. Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. Int J Hematol 2008;88:227–36
   PubMed Web of Science ®Google Scholar
• Jensen SA, Hasbak P, Mortensen J, Sorensen JB. Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. J Clin Oncol 2010;28:5280–6
   PubMed Web of Science ®Google Scholar
• Romano S, Fratini S, Ricevuto E, et al. Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer 2011;105:1663–8
   PubMed Web of Science ®Google Scholar
• Broeyer FJ, Osanto S, Ritsema van Eck HJ, et al. Evaluation of biomarkers for cardiotoxicity of anthracycline-based chemotherapy. J Cancer Res Clin Oncol 2008;134:961–8
   PubMed Web of Science ®Google Scholar
• Ekstein S, Nir A, Rein AJ, et al. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children. J Pediatr Hematol Oncol 2007;29:440–4
   PubMed Web of Science ®Google Scholar
• Auner HW, Tinchon C, Linkesch W, et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 2003;82:218–22
   PubMed Web of Science ®Google Scholar
• Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000;36:517–22
   PubMed Web of Science ®Google Scholar
• Katsurada K, Ichida M, Sakuragi M, et al. High-sensitivity troponin T as a marker to predict cardiotoxicity in breast cancer patients with adjuvant trastuzumab therapy. Springerplus 2014;3:620. doi: 10.1186/2193-1801-3-620. eCollection 2014
   PubMed Web of Science ®Google Scholar
• Hayakawa H, Komada Y, Hirayama M, et al. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 2001;37:4–9
   PubMedGoogle Scholar
• Pinarli FG, Oguz A, Tunaoglu FS, et al. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. Pediatr Blood Cancer 2005;44:370–7
   PubMed Web of Science ®Google Scholar
• Kittiwarawut A, Vorasettakarnkij Y, Tanasanvimon S, et al. Serum NT-proBNP in the early detection of doxorubicin-induced cardiac dysfunction. Asia Pac J Clin Oncol 2013;9:155–61
   PubMed Web of Science ®Google Scholar
• Ky B, Putt M, Sawaya H, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 2014;63:809–16
   PubMed Web of Science ®Google Scholar
• Putt M, Hahn VS, Januzzi JL, et al. Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab. Clin Chem 2015;61:1164–72
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004;351:145–53
   PubMed Web of Science ®Google Scholar
• Grover S, Leong DP, Chakrabarty A, et al. Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: a prospective study using novel cardiac imaging and biochemical markers. Int J Cardiol 2013;168:5465–7
   PubMed Web of Science ®Google Scholar
• Kismet E, Varan A, Ayabakan C, et al. Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin. Pediatr Blood Cancer 2004;42:220–4
   PubMed Web of Science ®Google Scholar
• Dodos F, Halbsguth T, Erdmann E, Hoppe UC. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 2008;97:318–26
   PubMed Web of Science ®Google Scholar
• Onitilo AA, Engel JM, Stankowski RV, et al. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. Breast Cancer Res Treat 2012;134:291–8
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Miller TL, Scully RE, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol 2012;30:1042–9
   PubMed Web of Science ®Google Scholar
• Yaris N, Ceviz N, Coskun T, et al. Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity. J Exp Clin Cancer Res 2002;21:165–70
   PubMed Web of Science ®Google Scholar
• Guler E, Baspinar O, Cekmen M, et al. Nitric oxide: a new biomarker of Doxorubicin toxicity in children? Pediatr Hematol Oncol 2011;28:395–402
   PubMed Web of Science ®Google Scholar
• Perik PJ, Van der Graaf WT, De Vries EG, et al. Circulating apoptotic proteins are increased in long-term disease-free breast cancer survivors. Acta Oncol 2006;45:175–83
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010;28:3910–16
   PubMed Web of Science ®Google Scholar
• Sawaya H, Sebag IA, Plana JC, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 2011;107:1375–80
   PubMed Web of Science ®Google Scholar
• Morris PG, Chen C, Steingart R, et al. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res 2011;17:3490–9
   PubMed Web of Science ®Google Scholar
• McArthur HL, Rugo H, Nulsen B, et al. A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clin Cancer Res 2011;17:3398–407
   PubMed Web of Science ®Google Scholar
• Zhu W, Soonpaa MH, Chen H, et al. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation 2009;119:99–106
   PubMed Web of Science ®Google Scholar
• Ichikawa Y, Ghanefar M, Bayeva M, et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest 2014;124:617–30
   PubMed Web of Science ®Google Scholar
• Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012;18:1639–42
   PubMed Web of Science ®Google Scholar
• Wadia S. Acute cyclophosphamide hemorrhagic myopericarditis: dilemma case report, literature review and proposed diagnostic criteria. J Clin Diagn Res 2015;9:OE01–OE3. doi: 10.7860/JCDR/2015/15054.6758. Epub 2015 Nov 1
   Google Scholar
• Kandylis K, Vassilomanolakis M, Tsoussis S, Efremidis AP. Ifosfamide cardiotoxicity in humans. Cancer Chemother Pharmacol 1989;24:395–6
   PubMed Web of Science ®Google Scholar
• Sayed-Ahmed MM, Aldelemy ML, Al-Shabanah OA, et al. Inhibition of gene expression of carnitine palmitoyltransferase I and heart fatty acid binding protein in cyclophosphamide and ifosfamide-induced acute cardiotoxic rat models. Cardiovasc Toxicol 2014;14:232–42
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991;9:1704–12
   PubMed Web of Science ®Google Scholar
• Zhang K, Heidrich FM, DeGray B, et al. Paclitaxel accelerates spontaneous calcium oscillations in cardiomyocytes by interacting with NCS-1 and the InsP3R. J Mol Cell Cardiol 2010;49:829–35
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666–76
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427–34
   PubMed Web of Science ®Google Scholar
• Blackwell K, Hurwitz H, Lieberman G, et al. Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer 2004;101:77–82
   PubMed Web of Science ®Google Scholar
• Qi WX, Fu S, Zhang Q, Guo XM. Bevacizumab increases the risk of severe congestive heart failure in cancer patients: an up-to-date meta-analysis with a focus on different subgroups. Clin Drug Investig 2014;34:681–90
   PubMed Web of Science ®Google Scholar
• Patel JN, Jiang C, Hertz DL, et al. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer 2015;121:1025–31
   PubMed Web of Science ®Google Scholar
• Suter TM, Cook-Bruns N, Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 2004;13:173–83
   PubMed Web of Science ®Google Scholar
• Bordun KA, Premecz S, daSilva M, et al. The utility of cardiac biomarkers and echocardiography for the early detection of bevacizumab- and sunitinib-mediated cardiotoxicity. Am J Physiol Heart Circ Physiol 2015;309:H692–701
   PubMed Web of Science ®Google Scholar
• Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol 2009;48:964–70
   PubMed Web of Science ®Google Scholar
• Varga ZV, Ferdinandy P, Liaudet L, Pacher P. Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol 2015;309:H1453–67
   PubMed Web of Science ®Google Scholar
• Meseeha MG, Kolade VO, Attia MN. Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy. J Community Hosp Intern Med Perspect 2015;5:28982. doi: 10.3402/jchimp.v5.28982. eCollection 2015
   PubMed Web of Science ®Google Scholar
• Nowis D, Maczewski M, Mackiewicz U, et al. Cardiotoxicity of the anticancer therapeutic agent bortezomib. Am J Pathol 2010;176:2658–68
   PubMed Web of Science ®Google Scholar
• Pongprot Y, Sittiwangkul R, Charoenkwan P, Silvilairat S. Use of cardiac markers for monitoring of doxorubicin-induced cardiotoxicity in children with cancer. J Pediatr Hematol Oncol 2012;34:589–95
   PubMed Web of Science ®Google Scholar